

Brief Correspondence

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer

Greg L. Shaw^{a,b,i,*}, Hayley Whitaker^{a,j}, Marie Corcoran^b, Mark J. Dunning^a, Hayley Luxton^{a,j}, Jonathan Kay^{a,j}, Charlie E. Massie^a, Jodi L. Miller^a, Alastair D. Lamb^{a,b}, Helen Ross-Adams^a, Roslin Russell^a, Adam W. Nelson^{a,b}, Matthew D. Eldridge^a, Andrew G. Lynch^a, Antonio Ramos-Montoya^a, Ian G. Mills^{d,e,f}, Angela E. Taylor^g, Wiebke Arlt^g, Nimish Shah^b, Anne Y. Warren^c, David E. Neal^{a,b,h}

^aCancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK; ^bDepartment of Urology, Cambridge University Hospitals NHS Trust, Cambridge, UK; ^cDepartment of Pathology, Cambridge University Hospitals NHS Trust, Cambridge, UK; ^dProstate Cancer Research Group, Nordic EMBL Partnership, Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway; ^eDepartments of Cancer Prevention and Urology, Institute of Cancer Research and Oslo University Hospitals, Oslo, Norway; ^fProstate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK; ^gCentre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, UK; ^hNuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK; ⁱUniversity College Hospitals NHS Trust, UK; ^jUniversity College London, London, UK

Article info

Article history:

Accepted October 20, 2015

Associate Editor:

James Catto

Keywords:

Prostate cancer
Androgen receptor
Castration
Clinical trial
Immunohistochemistry
Gene transcription

Abstract

The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore, understanding how ARs regulate the human transcriptome is of paramount importance. The early effects of castration on human PCa have not previously been studied 27 patients medically castrated with degarelix 7 d before radical prostatectomy. We used mass spectrometry, immunohistochemistry, and gene expression array (validated by reverse transcription-polymerase chain reaction) to compare resected tumour with matched, controlled, untreated PCa tissue. All patients had levels of serum androgen, with reduced levels of intraprostatic androgen at prostatectomy. We observed differential expression of known androgen-regulated genes (*TMPRSS2*, *KLK3*, *CAMKK2*, *FKBP5*). We identified 749 genes downregulated and 908 genes upregulated following castration. AR regulation of α -methylacyl-CoA racemase expression and three other genes (*FAM129A*, *RAB27A*, and *KIAA0101*) was confirmed. Upregulation of oestrogen receptor 1 (ESR1) expression was observed in malignant epithelia and was associated with differential expression of ESR1-regulated genes and correlated with proliferation (Ki-67 expression).

Patient summary: This first-in-man study defines the rapid gene expression changes taking place in prostate cancer (PCa) following castration. Expression levels of the genes that the androgen receptor regulates are predictive of treatment outcome. Upregulation of oestrogen receptor 1 is a mechanism by which PCa cells may survive despite castration.

© 2015 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

* Corresponding author. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, United Kingdom. Tel. +44 0 1223 769500; Fax: +44 0 1223 769007. E-mail address: gregshaw@doctors.org.uk (G.L. Shaw).

Prostate cancer (PCa) is the second most common cause of cancer death in men in the developed world [1]. The androgen receptor (AR) controls PCa growth. Previously, studies of the long-term effects (>3 mo) of medical castration have demonstrated differing transcriptional response following luteinising hormone-releasing hormone (LHRH) analogue and antiandrogens [2] and have implicated Wnt/ β -catenin signalling in castration-resistant PCa [3]. We used a new drug called degarelix to rapidly decrease testosterone levels and inform the early in vivo response of human PCa to castration.

1. Patients and methods

1.1. Study approval

We obtained full ethics approval for all elements of studies NCT01852864 (REC ref:11/H0311/2) and NCT00967889 (REC ref:01/4/061).

1.2. Clinical sample collection

Twenty-seven patients with high-risk PCa (according to the D'Amico classification) [4] were administered 240 mg subcutaneous degarelix (donated by Ferring Pharmaceuticals Inc, Parsippany, NJ, USA) 7 d before radical prostatectomy (RP) (Supplementary Fig. 1a). These patients were matched for risk factors (age, serum prostate-specific antigen, tumour grade and stage) with 20 patients undergoing RP without neoadjuvant degarelix (Supplementary Table 1). Study and control patients underwent surgery contemporaneously using standard operative technique, with similar ischemic time before sampling as described [5]. Serum samples were obtained at 8 AM prior to surgery.

1.3. Assay of androgen levels in body fluids and tissue

Fresh frozen prostate cores were homogenised, and steroids were extracted and quantified by liquid chromatography coupled with tandem mass spectrometry.

1.4. Gene expression profiling

We hybridised mRNA onto Illumina HumanHT-12 v4 Expression BeadChips (Illumina, San Diego, CA, USA).

1.5. Accession numbers

Study data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE72920. Expression data were validated for known AR-regulated genes (*KLK3*, *FASN*), genes found to be AR regulated in our expression data with known AR binding sites in promoter regions [6] (*FAM129A*, *KIAA0101*, *RAB27A*) and genes of biological importance (*AMACR*, *ESR1*, cyclin D1) by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC).

1.6. Quantitative real-time polymerase chain reaction

We performed RT-PCR in triplicate using SYBR Green and the 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).

1.7. Human tissue microarray construction and immunohistochemistry

PCa samples (index lesion) from 27 patients were identified on the haematoxylin and eosin-stained sections from formalin-fixed

paraffin-embedded RP specimens and marked (A.W.). Triplicate 2-mm tumour cores were taken from these areas and re-embedded in human tissue microarray (TMA) paraffin blocks.

We used a BOND-III automated stainer (Leica Biosystems, Buffalo Grove, IL, USA) and Bond Polymer Refine Detection Kit (Leica Biosystems) for IHC. Scoring was by two blinded observers (including A.W.) until consensus was reached. Staining intensity was classified as 0 (none), 1 (weak), 2 (moderate), and 3 (high). For nuclear staining (*ESR1*, Ki-67, and *CCND1*), we used the following modified scoring systems to quantify the number of moderately or intensely staining nuclei as a proportion of all the malignant epithelial cells: *ESR1* and *CCND1* staining (0, no intensely staining positive nuclei; 1, 0.1–10% intensely stained nuclei per core; 2, 10–20% intensely staining nuclei per core; 3, >20% stained nuclei per core) and Ki-67 staining (0, no positive nuclei; 1, 1–5% positive nuclei; 2, 5–10% positive nuclei; 3, >10% positive nuclei).

1.8. Statistical analysis

All data are quoted as median plus or minus interquartile range, and *p* values <0.05 were considered significant. We use the paired *t* test for paired data; for unpaired data, we used an unpaired *t* test for parametric data and the Mann-Whitney test for nonparametric data. For TMA IHC scoring analysis, we computed the mean intensities for each sample and performed a Mann-Whitney test.

1.9. Gene set enrichment analysis

We used Gene Set Enrichment Analysis (GSEA) version 2.0.14 (The Broad Institute, Cambridge, MA, USA). We used the Reactome version 3.0 database to analyse differentially expressed genes (DEGs) following castration for enrichment of predefined gene sets. Using the JASPAR database in the Pscan Web interface (version 1.3), we analysed 500 bases upstream of the top 500 DEGs for enriched transcription factor binding sites (Fig. 2C).

2. Results

We saw no differences in the tumour or patient characteristics of the study and control cohorts (Supplementary Table 1). We saw a rapid decrease in the serum testosterone at 7 d after degarelix administration in all treated patients (11.73 ± 5.08 vs 1.19 ± 0.63 nmol/l) (Supplementary Fig. 1B), paralleled by a decrease in intratumoural androgens (Supplementary Fig. 1C). We identified 749 genes downregulated and 908 genes upregulated in response to castration. Expression levels of known AR-regulated genes—including *TMPRSS2*, *FKBP5*, *KLK3*, and *FASN*—were among those most strongly affected by treatment (Supplementary Table 2 and 3). We validated differential expression for eight genes by RT-PCR and IHC (Fig. 1B and 1C).

Degarelix treatment decreased nuclear expression of proliferation marker Ki-67 protein and cell cycle progression (expression of nuclear *CCND1*) (Fig. 1B and 1C). We observed and validated decreased expression of three genes with limited evidence of AR regulation but with AR binding sites in their promoter regions (*RAB27A*, *KIAA0101*, and *FAM129A*) following degarelix treatment (Fig. 1A–1C).

2.1. *ESR1* expression is upregulated in malignant epithelia, is pro-proliferative, and is associated with transcription of known *ESR1* target genes

Degarelix treatment upregulated *ESR1* mRNA (Fig. 2A). Using GSEA, we demonstrated enrichment of genes that had

Download English Version:

<https://daneshyari.com/en/article/6175708>

Download Persian Version:

<https://daneshyari.com/article/6175708>

[Daneshyari.com](https://daneshyari.com)